AirSculpt 2025 Q3 Earnings Revenue Falls 17.8% as Loss Widens 57.5%

AirSculpt Technologies (AIRS) reported Q3 2025 results that missed expectations, with revenue declining 17.8% year-over-year to $34.99 million and net loss widening to $9.51 million (vs. $6.04 million in 2024). The company cut full-year revenue guidance to $153 million from $160–170 million, signaling weaker demand in the body-contouring market.

Revenue

The total revenue of AirSculpt decreased by 17.8% to $34.99 million in 2025 Q3, down from $42.55 million in 2024 Q3.

Earnings/Net Income

AirSculpt's losses deepened to $0.15 per share in 2025 Q3 from a loss of $0.10 per share in 2024 Q3 (50.0% wider loss). Meanwhile, the company's net loss widened to $-9.51 million in 2025 Q3, representing a 57.5% increase from the $-6.04 million loss recorded in 2024 Q3. The EPS is bad, reflecting deteriorating profitability.

Price Action

The stock price of AirSculpt has plummeted 16.16% during the latest trading day, has plummeted 41.21% during the most recent full trading week, and has plummeted 28.42% month-to-date.

Post-Earnings Price Action Review

The strategy of buying AirSculpt (AIRS) shares on the date of its revenue raise and holding for 30 days yielded mixed results over the past three years. Overall, the strategy generated a 25.8% gain over three years, outperforming the S&P 500’s 14.3% return, but exhibited significant volatility. For instance, Q3 2023 saw a 102.1% surge following a strong revenue beat, while Q4 2023 and Q1 2024 experienced a -43% drop after the revenue decline and guidance cut, followed by a partial recovery. The stock remained relatively stable in Q2 and Q3 2024 but still declined by -17.8% year-to-date. Key takeaways include the stock’s proneness to volatility post-earnings, the mitigating effect of long-term holding, and the critical role of market sentiment in driving price movements. In conclusion, while the strategy has potential for substantial gains, it carries risks due to post-earnings volatility, requiring a cautious, long-term approach.

CEO Commentary

Yogesh Jashnani (CEO & Director) highlighted Q3 revenue fell short due to timing, not trajectory, emphasizing AirSculpt’s focus on new growth opportunities like GLP-1-related body contouring. He outlined three strategic priorities: introducing skin tightening and excision procedures to address GLP-1-induced loose skin, enhancing sales/marketing strategies with targeted campaigns, and maintaining financial discipline via $3M+ annualized cost savings and $18M debt repayment. Jashnani noted GLP-1 patients represent a durable opportunity, with higher conversion rates observed in pilots, and expressed confidence in long-term growth despite near-term revenue challenges. Leadership remains cautiously optimistic, balancing strategic investments with margin improvement and debt reduction.

Guidance

AirSculpt revised 2025 revenue guidance to ~$153M (down from $160–170M) and expects EBITDA of ~$16M (lower bound of prior $16–18M range). For Q4, management anticipates smaller revenue declines YoY, improved same-store sales, and stronger margins sequentially and YoY. The company prioritizes debt repayment, having repaid $18M year-to-date, and plans to expand.

Additional News

AirSculpt announced the appointment of Michael Arthur as CFO effective January 2026, succeeding Dennis Dean, who will retire. The company also closed its London center, the only unprofitable location, to prioritize North American growth. Additionally, AirSculpt expanded skin tightening and excision pilot programs to address GLP-1-related loose skin, positioning itself to capitalize on a growing market segment. These strategic moves aim to enhance long-term growth while maintaining financial discipline.